Intercell starts Pseudomonas vaccine trial to help Novartis decide on option
This article was originally published in Scrip
Executive Summary
Intercell has begun a pivotal Phase II/III efficacy trial of its investigational Pseudomonas aeruginosa vaccine which is part of an alliance with Novartis. The study will be conducted by Intercell and costs will be shared between both parties. Novartis had been expected to make a decision on whether or not it would exercise its option for rights to the IC43 recombinant subunit candidate vaccine, consisting of two outer membrane proteins of P.aeruginosa, during the first half of last year (scripintelligence.com, 1 April 2011). However, the companies decided to run additional studies to help Novartis make a final decision.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.